TAX 327
Sep 17, 2020•14 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
The Landmarks in OncoPharm series returns to discuss a major breakthrough in treating advanced prostate cancer, TAX-327, which at the time established docetaxel as a new standard of care for metastatic prostate cancer that was (at that time) considered hormone-refractory.
TAX 327: https://www.nejm.org/doi/full/10.1056/NEJMoa040720
For the best experience, listen in Metacast app for iOS or Android